BELGRADE, Montana, August 28, 2026, 14:45 (MDT). Xtant Medical stock advanced 16% after BioHorizons agreed to introduce the Prolifica line to its dental sales channel, boosting access to the product in the dental sector.
- Xtant Medical finished the session at $0.384, rising 16.36%, with volume at 76.04 million shares.
- BioHorizons secures exclusive rights to distribute Xtant’s growth-factor technology within dental markets in the U.S. and Canada.
- The product is sold under the Prolifica private label from BioHorizons.
- Details regarding commercial economics and product pricing were not revealed.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) rose 16.36% on Friday following the launch of a new dental distribution channel. Shares finished at $0.384, with 76.04 million shares traded.
The surge increased Xtant’s market value by about $7.6 million, a significant figure compared to its $53.9 million capitalization. The revenue impact of the deal has not yet been specified.
Xtant’s allogeneic growth-factor technology will be distributed exclusively by BioHorizons in the United States and Canada. The agreement includes dental and oral-maxillofacial procedures. BioHorizons plans to market the technology under its Prolifica private label company announcement.
This product utilizes identical technology to Xtant’s OsteoFactor Pro, blending natural allogeneic growth factors with native human collagen. According to Xtant, its processing maintains a two-phase release of proteins.
| Company | Aug. 28 price | Daily move | Market value | Investor role |
|---|---|---|---|---|
| Xtant Medical (XTNT) | $0.384 | +16.36% | $53.9m | Developer and manufacturer in technology |
| Henry Schein (HSIC) | $89.52 | −0.85% | $10.24bn | Distribution platform and BioHorizons parent |
| Orthofix Medical (OFIX) | $9.70 | +0.73% | $396.8m | Peer in orthobiologics |
| Globus Medical (GMED) | $82.97 | +0.52% | $11.40bn | Peer specialising in musculoskeletal devices |
The disparity in scale shapes the potential. Henry Schein (NASDAQ: HSIC), the parent company of BioHorizons, has a market value close to 190 times that of Xtant. Its strong dental network could expand product reach, bypassing the need for Xtant to assemble an additional sales team.
Broad distribution does not ensure profitable sales. Both companies withheld details on pricing, minimum orders, royalties, and launch investment. Prolifica is currently on the market, though there was no disclosure of an initial order.
Xtant is seeking growth as revenue for the second quarter dropped 35% to $23.0 million, impacted by divestitures and the loss of license income. Gross margin narrowed by 10.7 percentage points to 57.9%.
The company reported a net loss of $9.4 million. Adjusted EBITDA turned negative at $2.7 million. Executives lowered their 2026 revenue outlook to $99 million–$103 million Xtant results.
Xtant ended Friday trading at around 0.53 times the midpoint of its guidance. The subdued multiple highlights ongoing concerns over performance and liquidity. As of June 30, the company reported $9.9 million in cash and $23.0 million in debt.
The dental channel further expands a company focused on spine and orthopedic uses. Prolifica has the potential to drive recurring demand if clinicians begin using it for bone regeneration. Data on market size and financial impact is still needed.
Risks: Xtant may face tight margins due to private-label agreements. Uptake might be gradual, and donor tissue supply and regulatory factors can act as hurdles. Limited liquidity could amplify price swings.
Friday’s trading volume highlights heightened investor interest. The next key factor is a commercial update—specifics on orders, revenue recognition, and gross-margin contribution from Prolifica. In the absence of these metrics, the rally reflects interest in access rather than demonstrated demand.
Related articles: Biotechnology
